BochevaGS, SlominskiRM, SlominskiAT. Immunological aspects of skin aging in atopic Dermatitis. Int J Mol Sci, 2021; 22(11).
3.
AndrewB, EmmaGY, AmySP, et al.Long-term efficacy and safety of Dupilumab in adolescents with moderate-to-severe atopic dermatitis: Results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol, 2022; 23(3):365–383.
4.
ZhouX, YangG, ChenX, et al.Efficacy and safety of Dupilumab in older patients (aged 80 years and above) with atopic dermatitis: A Prospective Study. Drugs Aging. 2023; 40(10):933–940.
5.
OwjiS, UngarB, DubinDP, et al.No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol Pract, 2023; 11(5):1548–1551.
